Article

Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan

Leiden University, Leyden, South Holland, Netherlands
Clinical Cancer Research (Impact Factor: 8.19). 12/2005; 11(21):7800-6. DOI: 10.1158/1078-0432.CCR-05-1288
Source: PubMed

ABSTRACT Milk thistle (Silybum marianum) is one of the most commonly used herbal therapies, and its principal constituent silybin significantly inhibits cytochrome P450 isoform 3A4 (CYP3A4) and UDP glucuronosyltransferase isoform 1A1 (UGT1A1) in vitro. Here, we investigated whether milk thistle affects the pharmacokinetics of irinotecan, a substrate for CYP3A4 and UGT1A1, in humans.
Six cancer patients were treated with irinotecan (dose, 125 mg/m(2)) given as a 90-minute infusion once every week. Four days before the second dose, patients received 200 mg milk thistle, thrice a day, for 14 consecutive days. Pharmacokinetic studies of irinotecan and its metabolites 7-ethyl-10-hydroxycamptothecin (SN-38), 7-ethyl-10-[3,4,5-trihydroxy-pyran-2-carboxylic acid]-camptothecin (SN-38-glucuronide), and 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin were done during the first three irinotecan administrations.
Short-term (4 days) or more prolonged intake of milk thistle (12 days) had no significant effect on irinotecan clearance (mean, 31.2 versus 25.4 versus 25.6 L/h; P = 0.16). The area under the curve ratio of SN-38 and irinotecan was slightly decreased by milk thistle (2.58% versus 2.23% versus 2.17%; P = 0.047), whereas the relative extent of glucuronidation of SN-38 was similar (10.8 versus 13.5 versus 13.1; P = 0.64). Likewise, the area under the curve ratio of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin and irinotecan was unaffected by milk thistle (0.332 versus 0.285 versus 0.337; P = 0.53). The maximum plasma concentrations of silybin ranged between 0.0249 and 0.257 micromol/L.
Silybin concentrations after intake of milk thistle are too low to significantly affect the function of CYP3A4 and UGT1A1 in vivo, indicating that milk thistle is unlikely to alter the disposition of anticancer drugs metabolized by these enzymes.

Download full-text

Full-text

Available from: Alex Sparreboom, May 13, 2015
0 Followers
 · 
125 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pharmacokinetic herb-drug interactions are caused by an induction or inhibition of cytochrome P450 (CYP) enzymes or transporters e.g. P-glycoprotein. St. John's wort extracts containing hyperforin increase the expression of CYP-enzymes and P-glycoprotein mainly in the gut and liver which leads to a clinically relevant decrease of the bioavailability of CYP and P-glycoprotein substrates. Contrarily, the bioactivation of the prodrug losartan is reduced by milk thistle extracts which is due to an inhibition of CYP2C9. However, the 15 % reduction of the bioavailability of the active metabolite E-3174 is clinically not relevant. Also, minor changes in drug bioavailability observed in clinical studies for valerian, echinacea, ginkgo and hawthorne are clinically not relevant, although in vitro studies point to drug interactions in vivo. Since for herbal extracts a positive in vitro - in vivo correlation regarding the impact on drug bioavailability is rare, results from in vitro studies should be carefully interpreted.
    Wiener Medizinische Wochenschrift 12/2010; 160(21-22):571-7.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pharmakokinetische Interaktionen zwischen synthetischen und pflanzlichen Arzneimitteln beruhen zumeist auf einer Induktion oder Inhibition der für die Bioverfügbarkeit von Arzneistoffen hauptsächlich verantwortlichen Cytochrom-P450 (CYP)-Enzyme und Transporter, wie z.B. P-Glykoprotein. Zum Beispiel führen hyperforinhaltige Johanniskrautextrakte nach einigen Tagen hauptsächlich in Leber und Dünndarm zu einer gesteigerten Expression von CYP-Enzymen und P-Glykoprotein. Dadurch wird die Bioverfügbarkeit von zahlreichen CYP- oder P-Glykoprotein-Substraten klinisch relevant erniedrigt. Im Gegensatz hierzu wird die Bioaktivierung des Prodrugs Losartan durch Mariendistelextrakte vermindert, was auf eine Hemmung von CYP2C9 zurückgeführt werden kann. Allerdings ist die Reduktion der Bioverfügbarkeit des aktiven Metaboliten E-3174 (15 %) klinisch nicht relevant. Auch die bei In-vivo-Studien beobachteten Änderungen der Arzneistoffbioverfügbarkeit durch z. B. Baldrian-, Echinacea-, Ginkgo- und Weißdornpräparate sind klinisch nicht relevant, obwohl zahlreiche In-vitro-Studien auf Interaktionen in vivo hindeuten. Da hinsichtlich der Beeinflussung von metabolischen Vorgängen oder Transportprozessen bei Phytopharmaka nur selten eine positive In-vitro-in-vivo-Korrelation vorliegt, sollten Ergebnisse aus In-vitro-Studien vorsichtig interpretiert werden. Pharmacokinetic herb-drug interactions are caused by an induction or inhibition of cytochrome P450 (CYP) enzymes or transporters e.g. P-glycoprotein. St. John's wort extracts containing hyperforin increase the expression of CYP-enzymes and P-glycoprotein mainly in the gut and liver which leads to a clinically relevant decrease of the bioavailability of CYP and P-glycoprotein substrates. Contrarily, the bioactivation of the prodrug losartan is reduced by milk thistle extracts which is due to an inhibition of CYP2C9. However, the 15 % reduction of the bioavailability of the active metabolite E-3174 is clinically not relevant. Also, minor changes in drug bioavailability observed in clinical studies for valerian, echinacea, ginkgo and hawthorne are clinically not relevant, although in vitro studies point to drug interactions in vivo. Since for herbal extracts a positive in vitro – in vivo correlation regarding the impact on drug bioavailability is rare, results from in vitro studies should be carefully interpreted. SchlüsselwörterArzneimittelinteraktionen-Cytochrom-P450-Enzyme-Johanniskraut-Pflanzliche Arzneimittel-P-Glykoprotein KeywordsDrug interactions-Cytochrome P450 enzymes-Herbal drugs-P-glycoprotein-St John's wort
    Wiener Medizinische Wochenschrift 12/2010; 160(21):571-577. DOI:10.1007/s10354-010-0848-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Conventional wisdom generally recommends complete avoidance of all dietary supplements, especially during chemotherapy and radiation. This interdiction persists, in spite of high rates of dietary supplement use by patients throughout all phases of cancer care, and can result in patients' perceptions of physicians as negative, thus leading to widespread nondisclosure of use. A review of the clinical literature shows that some evidence for harm does exist; however, data also exist that show benefit from using certain well-qualified supplements. Physicians should increase their knowledge base about dietary supplement use in cancer and consider all of the data when advising patients. Strategies that are patient-centered and reflect the complete array of available evidence lead to more nuanced messages about dietary supplement use in cancer. This should encourage greater disclosure of use by patients and ultimately increase safety and efficacy for patients choosing to use dietary supplements during cancer care.
    Hematology/Oncology Clinics of North America 08/2008; 22(4):581-617, vii. DOI:10.1016/j.hoc.2008.04.012 · 2.07 Impact Factor